Your browser doesn't support javascript.
loading
Metformin Affects Gut Microbiota Composition and Diversity Associated with Amelioration of Dextran Sulfate Sodium-Induced Colitis in Mice.
Liu, Zhiyi; Liao, Wangdi; Zhang, Zihan; Sun, Ruipu; Luo, Yunfei; Chen, Qiongfeng; Li, Xin; Lu, Ruiling; Ying, Ying.
Afiliação
  • Liu Z; Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Liao W; Queen Mary School, Nanchang University, Nanchang, China.
  • Zhang Z; Departments of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Sun R; Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Luo Y; Queen Mary School, Nanchang University, Nanchang, China.
  • Chen Q; Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Li X; Queen Mary School, Nanchang University, Nanchang, China.
  • Lu R; Department of Pathophysiology, Schools of Basic Medical Sciences, Nanchang University, Nanchang, China.
  • Ying Y; Department of Pathophysiology, Schools of Basic Medical Sciences, Nanchang University, Nanchang, China.
Front Pharmacol ; 12: 640347, 2021.
Article em En | MEDLINE | ID: mdl-34122067
ABSTRACT

Background:

Inflammatory bowel disease (IBD) is an increasingly common and globally emergent immune-mediated disorder. The etiology of IBD is complex, involving multiple factors such as immune dysregulation, environmental factors, genetic mutations, and microbiota dysbiosis, exacerbated by a lack of effective clinical therapies. Recently, studies hypothesized that dysbiosis of intestinal flora might participate in the onset of IBD. Metformin is widely used to treat type 2 diabetes and has shown beneficial effects in mouse models of IBD, although its underlying mechanisms remain poorly understood. Accumulating studies found that metformin shows beneficial effects for diabetes by affecting microbiota composition. This study explores possible regulatory effects of metformin on intestinal microecology during treatment for IBD.

Methods:

Inflammation was induced using 3% Dextran Sulfate Sodium (DSS) solution to generate mice models of IBD. Metformin treatments were assayed by measuring body weights and colon lengths of mice and H&E staining to observe histological effects on colon tissue structures. Changes in bacterial community composition and diversity-related to IBD and metformin treatment were assessed by high-throughput metagenomic sequencing analysis.

Results:

Metformin administration significantly ameliorated body weight loss, inhibited colon shrinking, and contributed to preserving the integrity of colon histological structures. The gut microbiota profiles revealed that the biodiversity of intestinal flora lost during inflammation was restored under metformin treatment. Metformin administration was also associated with decreased pathogenic Escherichia shigella and increased abundance of Lactobacillus and Akkermansia.

Conclusion:

Metformin appears to induce anti-inflammatory effects, thus ameliorating colitis symptoms, concurrent with enrichment for beneficial taxa and restored microbial diversity, suggesting a viable strategy against IBD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article